Single Use System in Biopharma Manufacturing Market, By Bioreactors (Less than 1000L, 1000-2000L, and More than 2000L), By Application (Filtration, Storage (Buffer & Media Storage, Freeze & Thaw), Cell Culture, Mixing, Purification, and Aseptic Filling),

Single Use System in Biopharma Manufacturing Market, By Bioreactors (Less than 1000L, 1000-2000L, and More than 2000L), By Application (Filtration, Storage (Buffer & Media Storage, Freeze & Thaw), Cell Culture, Mixing, Purification, and Aseptic Filling), By Bioprocessing (Small-scale, Mid-scale, and Large-scale), By Product (Sampling Systems, Bioprocess Containers, Bioreactors, Mixers, Membrane Absorbers, Bottles, Equipment, Transfer Units, and Others (Disposable filter Cartridges (DFC), Depth Filters, Clamps etc.)), By Modality (Protein & Monoclonal Antibody (Mab), Cell Therapy, Gene Therapy, Conventional Vaccine, and mRNA), By Component (Drug Substance and Drug Product), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Single use systems (SUS) refers to biopharmaceutical manufacturing equipment designed to be used once and then discarded. These systems are being increasingly used as an alternative to stainless-steel equipment for biopharma manufacturing. Single-use technologies offer both efficient & cost-effective way to manufacture biopharmaceuticals. In short, single use systems or technologies provide solutions that address the bioprocessing needs in the development and manufacturing of biopharmaceuticals. For instance, biopharmaceutical companies worldwide use single-use system to manufacture drugs and vaccines.

Market Dynamics:

Rising government support towards biosimilar & biological drugs, increasing acceptance and demand for biopharmaceuticals, ability of biopharmaceuticals to treat untreatable diseases, and growing biopharmaceutical manufacturing industry are some major factors expected to aid in the growth of the global single use system in biopharma manufacturing market.

In February 2021, Bristol Myers Squibb granted an exclusive license to develop, manufacture, and commercialize Rockefeller’s novel monoclonal antibody duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.

Moreover, in March 2020, Thermo Fisher Scientific Inc. invested around US$ 475 million to expand its biologics, cell therapy and gene therapy, and drug product development facilities and increase its global commercial capabilities.

Key features of the study:

• This report provides in-depth analysis of the global single use system in biopharma manufacturing market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global single use system in biopharma manufacturing market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Getinge AB, Rentschler Biopharma SE, Kühner AG, Danaher Corporation, Merck KgaA, Lonza, PBS Biotech Inc., ThermoFisher Scientific, Corning Incorporated, Eppendorf, Pall Corporation, Entegris, and Sartorius AG (Sartorius Stedim Biotech), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global single use system in biopharma manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global single use system in biopharma manufacturing market.

• Global Single Use System in Biopharma Manufacturing Market, By Bioreactors:
• Less than 1000L
• 1000-2000L
• More than 2000L
• Global Single Use System in Biopharma Manufacturing Market, By Application:
• Filtration
• Storage (Buffer & Media Storage, Freeze & Thaw)
• Cell Culture
• Mixing
• Purification
• Aseptic Filling
• Global Single Use System in Biopharma Manufacturing Market, By Bioprocessing:
• Small-scale
• Mid-scale
• Large-scale
• Global Single Use System in Biopharma Manufacturing Market, By Product:
• Sampling Systems
• Bioprocess Containers
• Bioreactors
• Mixers
• Membrane Absorbers
• Bottles
• Equipment
• Transfer Units
• Others (Disposable filter Cartridges (DFC), Depth Filters, Clamps etc.)
• Global Single Use System in Biopharma Manufacturing Market, By Modality:
• Protein & Monoclonal Antibody (Mab)
• Cell Therapy
• Gene Therapy
• Conventional Vaccine
• mRNA
• Global Single Use System in Biopharma Manufacturing Market, By Component:
• Drug Substance
• Drug Product
• Global Single Use System in Biopharma Manufacturing Market, By Geography:
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America
• Company Profiles:
• Getinge AB
• Rentschler Biopharma SE
• Kühner AG
• Danaher Corporation
• Merck KgaA
• Lonza
• PBS Biotech Inc.
• ThermoFisher Scientific
• Corning Incorporated
• Eppendorf
• Pall Corporation
• Entegris
• Sartorius AG (Sartorius Stedim Biotech)